Gilead Sciences’ COVID-19 drug Veklury (remdesivir) saw some rare year-over-year sales growth while the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) saw an even rarer decline in sales in the third quarter of 2024 as the drug maker raised its 2024 sales guidance.
Gilead Gears Up For CAR-T Data At ASH As Competition Weighs On Yescarta
The drug maker said in its third quarter earnings report that competition from other therapeutic classes, particularly bispecifics, resulted in a slight decline of sales for the CAR-T.
